Prevención con emapalumab de las toxicidades asociadas a las células CAR-T
Un ensayo de fase 2 de emapalumab para la prevención de toxicidades asociadas a las células CAR-T
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
- Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
- Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
- Emapalumab
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.
A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.
The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.
This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.
Once study treatment is completed, the participants will be followed for up to 24 months.
It is expected that about 28 people will take part in this research study.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Matthew Frigault, MD
- Número de teléfono: (617) 643-6175
- Correo electrónico: MFRIGAULT@partners.org
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Reclutamiento
- Massachusetts General Hospital
-
Investigador principal:
- Matthew Frigault, MD
-
Contacto:
- Matthew Frigault, MD
- Número de teléfono: 617-643-6175
- Correo electrónico: MFRIGAULT@partners.org
-
Boston, Massachusetts, Estados Unidos, 02215
- Aún no reclutando
- Dana-Farber Cancer Institute
-
Contacto:
- Caron Jacobson, MD
- Número de teléfono: (617)-632-5847
- Correo electrónico: Caron_Jacobson@DFCI.HARVARD.EDU
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
-
At least 1 measurable lesion per Lugano at time of screening.
-
Age 18 or older
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- ANC ≥1000/uL
- Platelet count ≥50,000/uL
- Absolute lymphocyte count ≥100/uL
- Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
- Serum ALT/AST ≤2.5 per institutional ULN
- Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
- Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
- Baseline oxygen saturation >92% on room air.
-
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.
-
Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.
-
History of allogeneic stem cell transplantation.
-
Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.
-
Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.
- Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
-
No evidence of active CNS disease regardless of prior CNS history.
-
History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.
-
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
-
History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.
-
Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
-
History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.
-
Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T
-
In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
-
History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.
-
Receipt of a BCG vaccine within 12 weeks prior to Screening.
-
Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.
-
Participants who are receiving any other investigational agents for this condition.
-
Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Cohort 1a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
Otros nombres:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
Experimental: Cohort 1b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
Otros nombres:
Alkylating agent Purine antagonist antimetabolite Autologous treatment Corticosteroid |
|
Experimental: Cohort 2a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
Otros nombres:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
Experimental: Cohort 2b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
Otros nombres:
Alkylating agent Purine antagonist antimetabolite Corticosteroid Autologous treatment |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of grade 2+ CRS per ASTCT
Periodo de tiempo: Day -1 to 24 months post treatment
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment. |
Day -1 to 24 months post treatment
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate and severity of ICANS as per ASTCT
Periodo de tiempo: 30 days
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion. |
30 days
|
|
Objective response rate (ORR)
Periodo de tiempo: Day -1 to 24 months post treatment
|
The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders. |
Day -1 to 24 months post treatment
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Duration of response (DOR)
Periodo de tiempo: From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing. |
From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Progression-free Survival (PFS)
Periodo de tiempo: From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date. |
From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Overall survival (OS)
Periodo de tiempo: From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date. |
From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Matthew Frigault, MD, Massachusetts General Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma de células B
- Linfoma
- Enfermedades hemic y linfáticas
- Linfoma de células B grandes, difuso
- Linfoma No Hodgkin
- Linfoma Folicular
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Hidrocarburos
- Compuestos policíclicos
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Esteroides, fluorado
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Esparrazadienetrioles
- Dexametasona
- Ciclofosfamida
- Anticuerpos Monoclonales
- fosfato de fludarabina
- axicabtagene ciloleucel
- Emapalumab
Otros números de identificación del estudio
Otros números de identificación del estudio
- 24-317
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Marco de tiempo para compartir IPD
Data can be shared no earlier than 1 year following the date of publication
Criterios de acceso compartido de IPD
Contact the Partners Innovations team at http://www.partners.org/innovation
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .